Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial

por Clark, Amy S., Yau, Christina, Wolf, Denise M., Petricoin, Emanuel F., van ‘t Veer, Laura J., Yee, Douglas, Moulder, Stacy L., Wallace, Anne M., Chien, A. Jo, Isaacs, Claudine, Boughey, Judy C., Albain, Kathy S., Kemmer, Kathleen, Haley, Barbara B., Han, Hyo S., Forero-Torres, Andres, Elias, Anthony, Lang, Julie E., Ellis, Erin D., Yung, Rachel, Tripathy, Debu, Nanda, Rita, Wulfkuhle, Julia D., Brown-Swigart, Lamorna, Gallagher, Rosa I., Helsten, Teresa, Roesch, Erin, Ewing, Cheryl A., Alvarado, Michael, Crane, Erin P., Buxton, Meredith, Clennell, Julia L., Paoloni, Melissa, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Steeg, Katherine, Asare, Adam, Matthews, Jeffrey B., Berry, Scott, Sanil, Ashish, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Schwab, Richard B., Symmans, W. Fraser, Hylton, Nola M., Berry, Donald A., Esserman, Laura J., DeMichele, Angela M.
Publicado 2021

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

por Lang, Julie E., Forero-Torres, Andres, Yee, Douglas, Yau, Christina, Wolf, Denise, Park, John, Parker, Barbara A., Chien, A. Jo, Wallace, Anne M., Murthy, Rashmi, Albain, Kathy S., Ellis, Erin D., Beckwith, Heather, Haley, Barbara B., Elias, Anthony D., Boughey, Judy C., Yung, Rachel L., Isaacs, Claudine, Clark, Amy S., Han, Hyo S., Nanda, Rita, Khan, Qamar J., Edmiston, Kristen K., Stringer-Reasor, Erica, Price, Elissa, Joe, Bonnie, Liu, Minetta C., Brown-Swigart, Lamorna, Petricoin, Emanuel F., Wulfkuhle, Julia D., Buxton, Meredith, Clennell, Julia L., Sanil, Ashish, Berry, Scott, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Asare, Adam L., Matthews, Jeffrey B., Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Symmans, W. Fraser, van ‘t Veer, Laura J., Hylton, Nola M., DeMichele, Angela M., Berry, Donald A., Esserman, Laura J.
Publicado 2022

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

por Yee, Douglas, Isaacs, Claudine, Wolf, Denise M., Yau, Christina, Haluska, Paul, Giridhar, Karthik V., Forero-Torres, Andres, Jo Chien, A., Wallace, Anne M., Pusztai, Lajos, Albain, Kathy S., Ellis, Erin D., Beckwith, Heather, Haley, Barbara B., Elias, Anthony D., Boughey, Judy C., Kemmer, Kathleen, Yung, Rachel L., Pohlmann, Paula R., Tripathy, Debu, Clark, Amy S., Han, Hyo S., Nanda, Rita, Khan, Qamar J., Edmiston, Kristen K., Petricoin, Emanuel F., Stringer-Reasor, Erica, Falkson, Carla I., Majure, Melanie, Mukhtar, Rita A., Helsten, Teresa L., Moulder, Stacy L., Robinson, Patricia A., Wulfkuhle, Julia D., Brown-Swigart, Lamorna, Buxton, Meredith, Clennell, Julia L., Paoloni, Melissa, Sanil, Ashish, Berry, Scott, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Asare, Adam L., Matthews, Jeffrey B., Hylton, Nola M., DeMichele, Angela, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Fraser Symmans, W., van‘t Veer, Laura J., Berry, Donald A., Esserman, Laura J.
Publicado 2021